Research

Research
The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Research in IMO

The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Ongoing projects

In the field of clinical research, the objective of projects currently under development is not only to improve the prognosis of patients with certain diseases, but also to offer, for the first time, an effective solution to diseases that are currently untreatable. This is also the ultimate goal of genetic studies, whose aim is to provide in-depth analysis of already known genes and identify new genes related to retinal dystrophies.
Investigación básica

Identification of new retinal dystrophy genes and characterisation of genotype/phenotype correlations

Retinal dystrophies (RD) are a heterogeneous group of hereditary diseases that are characterised by the degenerative effect that they have on the photoreceptors and cells of the retinal pigment epithelium.

Investigación clínica

Harrier

Phase III: Two-year, randomised, double-blind, multicentre, two-group trial comparing the efficacy and safety of 6 mg RTH258 compared to aflibercept in subjects with wet age-related macular degeneration.

Investigación clínica

Premed

Phase IV: Prevention of macular oedema in cataract surgery. PREMED. Non-commercial research.

Project history

The ophthalmologists, optometrists and nurses who specialise in ocular photography at the IMO carry out several multicentre clinical trials a year, of which the IMO is often the coordinator or main leading centre in Spain. These trials join the pioneering projects carried out by the genetics laboratory.
Investigación clínica

Aqua

Open-label phase IV trial to examine the change of vision-related quality of life in subjects with diabetic macular oedema (DMO) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.